LM-168 / Sino Biopharm, LaNova Medicines Limited - LARVOL DELTA

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=87 | Recruiting | Sponsor: LaNova Medicines Limited | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Solid Tumor

Preclinical evaluation of LM-168: A next-generation anti-CTLA4 antibody with promising efficacy and reduced toxicity (AACR 2025) - "Tumor infiltrating lymphocytes were analyzed after treatment with either LM-168 or ipilimumab. By targeting CTLA-4 conditionally, LM-168 is designed to address the potency and tolerability challenges associated with current anti-CTLA-4 antibodies, and thus has the potential to be a next generation CTLA-4 target therapy with promising clinical efficacy and reduced toxicity. LM-168 is also expected act synergistically with anti-PD-1/PD-L1 therapy. The preclinical data support clinical development of LM-168."

Preclinical • Oncology • CD8